**

Oxford Biomedica plc (OXB:L), a leading global cell therapy company specializing in lentiviral vector manufacturing, has announced the completion of its acquisition of the remaining 10% stake in its US subsidiary, Oxford Biomedica Solutions, Inc. (OBSI). This strategic move marks a significant milestone for the company, solidifying its presence in the lucrative North American cell and gene therapy market and enhancing its manufacturing capabilities. The acquisition underscores Oxford Biomedica's commitment to expanding its global reach and strengthens its position as a key player in the rapidly growing cell and gene therapy industry.

Oxford Biomedica's Strategic Acquisition: A Deep Dive

The acquisition of the final 10% stake in OBSI concludes a multi-year process for Oxford Biomedica, allowing for complete ownership and control over its vital US operations. This strategic move carries several key benefits, including:

• Enhanced Operational Control: Complete ownership allows Oxford Biomedica to streamline decision-making processes, optimize resource allocation, and implement strategic initiatives more efficiently within its North American operations.
• Increased Manufacturing Capacity: OBSI plays a critical role in Oxford Biomedica's global manufacturing network. The full acquisition ensures continued access to and expansion of this crucial manufacturing capacity to meet the increasing demand for lentiviral vectors.
• Strengthened Market Position: The complete acquisition reinforces Oxford Biomedica's position in the competitive North American cell and gene therapy market. This consolidation strengthens their ability to attract new clients and secure lucrative partnerships.
• Improved Financial Reporting: Owning 100% of OBSI simplifies financial reporting and consolidates revenue streams, providing investors with a clearer and more comprehensive view of the company's overall performance.

This strategic move is anticipated to significantly improve Oxford Biomedica’s overall financial performance, leading to improved revenue and potentially higher profits. This makes it an attractive investment for those interested in the cell and gene therapy market and the company's future growth trajectory.

Lentiviral Vector Manufacturing: A Booming Market

The global demand for lentiviral vectors, the core technology of Oxford Biomedica, is experiencing explosive growth. Driven by the rapidly advancing field of cell and gene therapy, companies are increasingly outsourcing the manufacturing of these crucial components to specialized manufacturers like Oxford Biomedica. This acquisition strengthens Oxford Biomedica's ability to capitalize on this burgeoning market.

Key Factors Driving the Demand for Lentiviral Vectors:

• Increased clinical trials: The number of clinical trials using cell and gene therapy is rapidly increasing, fueling the demand for large-scale lentiviral vector manufacturing.
• FDA approvals: The approval of new cell and gene therapies by the FDA and other regulatory bodies creates a significant market for commercial manufacturing.
• Technological advancements: Ongoing advancements in lentiviral vector technology are expanding its applications and further fueling the market's growth.
• Rising investments: Venture capital and pharmaceutical investments in the cell and gene therapy sector are significantly increasing, leading to a greater need for high-quality manufacturing capabilities.

The acquisition of the remaining stake in OBSI directly addresses these factors, positioning Oxford Biomedica to effectively meet the escalating demands of its clients and capitalize on the rapidly expanding market.

Impact on Shareholders and Investors

The acquisition of the remaining 10% stake is expected to have a positive impact on Oxford Biomedica's shareholders and investors. The enhanced operational efficiency, increased manufacturing capacity, and strengthened market position are all expected to translate into improved financial results. This should contribute to an increased valuation of the company and potentially higher returns for investors.

Future Outlook for Oxford Biomedica

Oxford Biomedica is well-positioned for continued growth in the cell and gene therapy sector. This acquisition, coupled with the company's ongoing research and development efforts and strategic partnerships, suggests a bright future for the company. The company's strategic focus on lentiviral vector technology positions them at the forefront of this rapidly expanding market.

The completion of the OBSI acquisition significantly contributes to the company's long-term growth strategy. This is a clear demonstration of the company's confidence in the future of cell and gene therapy and their commitment to building a dominant presence in the global market. The company's commitment to innovation and strategic acquisitions such as this one should continue to fuel their success.

Keywords for SEO Optimization:

• Oxford Biomedica
• Oxford Biomedica Solutions Inc. (OBSI)
• Lentiviral vector
• Cell and gene therapy
• Manufacturing capacity
• Acquisition
• North American market
• Pharmaceutical industry
• Biotechnology
• Clinical trials
• FDA approval
• Shareholder value
• Investment opportunities
• Global expansion
• Strategic partnerships
• Revenue growth
• Market capitalization
• Cell therapy manufacturing
• Gene therapy manufacturing

This acquisition represents a significant step forward for Oxford Biomedica, cementing its position as a leader in the rapidly expanding cell and gene therapy market. The complete ownership of OBSI allows for greater control, efficiency, and scalability, paving the way for future growth and success. The company's strategic actions strongly suggest continued expansion and a positive outlook for the future.